Neogen Chemicals Q4 FY26: Growth holds up as the battery materials build-out accelerates

Neogen Chemicals ended Q4 FY26 with a clear contrast in its story: steady execution in the core specialty chemicals business and a capital-heavy transition into battery materials that is shaping near-term profitability and the balance sheet.

On a consolidated basis, revenue for Q4 FY26 rose 22 percent year on year to INR 247 crore, while EBITDA increased 21 percent to INR 44 crore. Profit after tax jumped to INR 11 crore from INR 2 crore a year ago, helped by a low base that included one-off expenses linked to the Dahej fire incident. For the full year, consolidated revenue grew 11 percent to INR 862 crore. But EBITDA was flat at INR 137 crore and PAT declined 17 percent to INR 29 crore, reflecting higher finance costs and expansion overheads at Neogen Ionics.

Standalone numbers told a similar story of volume-led growth with pressure on margins. Q4 FY26 standalone revenue increased 22 percent to INR 249 crore and EBITDA increased 10 percent to INR 45 crore. Standalone PAT rose to INR 15 crore from INR 5 crore. For FY26, standalone revenue grew 11 percent to INR 855 crore, EBITDA increased 3 percent to INR 151 crore, while PAT edged down 3 percent to INR 47 crore.

The quarter was delivered in a noisy operating environment. Management highlighted supply chain disruption and elevated input costs partly stemming from Middle East geopolitical tensions. The company said it has pass-through mechanisms for higher input costs, including packaging materials, which helped protect core profitability even as margins softened.

Q4 performance: volumes, utilization, and a shifting mix

Neogen’s Q4 FY26 performance leaned on throughput. The company pointed to sustained high plant utilization and rising volumes, which helped maintain supply despite the ongoing transition at the Dahej site. Consolidated EBITDA margins were sustained at 17.8 percent in Q4 FY26, broadly stable versus the prior year quarter.

A notable shift was the spike in inorganic chemicals in the quarter. On a consolidated basis, inorganic chemicals revenue rose to INR 53 crore in Q4 FY26 from INR 22 crore in Q4 FY25, a 145 percent increase. Organic chemicals revenue grew 7 percent to INR 194 crore from INR 181 crore. For the full year, organic chemicals revenue increased 10 percent to INR 734 crore and inorganic chemicals grew 14 percent to INR 128 crore.

In terms of revenue mix for Q4 FY26, domestic sales accounted for 71 percent and exports were 29 percent, including deemed exports. Organic contribution was 79 percent and inorganic contribution was 21 percent.

Neogen Ionics, the battery chemicals subsidiary, remained a small but steady contributor during the year. Q4 FY26 revenue was INR 13 crore and FY26 revenue was INR 36 crore. The more important impact today is not topline but the cost of building capacity and qualifying products with customers, which is flowing through the P and L as expansion overheads and through the balance sheet as higher debt.

The margin trend explains much of the year-on-year divergence between revenue growth and profit growth. Consolidated EBITDA margin fell to 15.9 percent in FY26 from 17.5 percent in FY25. On the standalone side, EBITDA margin declined to 17.7 percent from 19.0 percent.

Finance costs were another drag. Consolidated interest expense rose to INR 75 crore in FY26 from INR 49 crore in FY25, reflecting capex deployment for Neogen Ionics and the Dahej facility rebuild. Standalone interest expense increased to INR 80 crore from INR 51 crore.

Dahej normalization: insurance receipts and a June 2026 milestone

The Dahej fire incident remains a key operational and financial reference point. In Q4 FY26, the company disclosed that cumulative on-account insurance claim received stood at INR 140 crore, and salvage realization at INR 7 crore. This included a tranche of INR 60 crore received in February 2026. Net claim receivable as on date stood at INR 203 crore.

Reconstruction of the replacement plant is on track, with commissioning expected by June 2026. This matters because FY26 performance still carried transition costs. Management cited one-off Dahej replacement and toll manufacturing costs, and indicated momentum should improve as the company shifts back to a normalized trajectory, supported by better fixed-cost absorption as upcoming Pakhajan and Dahej sites scale up, with further support from eligible insurance recoveries.

Investors should read this as a two-speed recovery. Q4 results showed that Neogen could keep volumes moving despite disruptions. But the full benefit of restored in-house production and fixed-cost absorption is expected only after commissioning and ramp-up.

Battery materials: timelines reset, capex expanded, and qualification underway

Neogen’s strategic pivot is most visible in battery materials through Neogen Ionics. The company has revised timelines and capital outlay for Dahej Phase 1 and Pakhajan Phase 2 battery materials projects. The aggregate project cost has been revised to INR 1,795 crore.

Dahej Phase 1 cost has been revised to INR 428 crore with expected completion by February 2027. Pakhajan Phase 2 cost stands revised to INR 1,367 crore with expected completion by March 2027. The company attributed the revision to design optimization following a transition from in-house processes to advanced Japanese technologies, and higher localization of critical sub-components to reduce import dependence and improve long-term operational reliability.

Capacity planning shows the scale of ambition. At Dahej SEZ, the plan includes electrolyte capacity of 2,000 MT and lithium electrolyte salts and additives capacity moving from 400 MT in FY25 to 1,100 MT in FY26 and a further 1,000 MT in FY27. The new Pakhajan site at Dahej PCPIR, with land area of 264,285 square meters, targets 30,000 MT of electrolytes and 3,000 MT of lithium electrolyte salts and additives in FY27. Across locations, total planned capacity is 32,000 MT of electrolytes and 5,500 MT of lithium electrolyte salts and additives.

Execution progress is moving in stages. For lithium electrolyte salts and additives, 200 MTPA has been commissioned and first approval material has been shipped to customers. For the remaining 1,300 MTPA, trial production is ongoing. A new 1,000 MT capacity is expected to be commissioned by Q3 FY27 and an additional 500 MT intermediate is also expected by Q3 FY27. The 2,000 MT electrolyte plant at Dahej was fully commissioned in FY25.

Customer qualification is a central theme. The company said provisional approvals have been received from additional international customers for lithium salts and final site audits are completed for three US-based electrolyte makers, awaiting final clearance. Management expects this to help transition from provisional to commercial-ready status by the end of the first half.

The strategic context is also evolving quickly. The presentation highlighted the push for non-Chinese supply chains, driven by regulatory incentives in the US and the need for compliance with Foreign Entity of Concern guidelines to secure US government tax credits. The document noted that many international customers are accelerating supplier transitions during 2026, with full transition expected by 2027.

India’s policy backdrop is supportive too. Neogen cited the government’s PLI scheme for advanced chemistry cell batteries, with an incentive outlay of INR 18,100 crore, 50 GWh of manufacturing capacity, and a target of 60 percent indigenous battery material. The company presented India lithium cell demand estimates rising from 15 GWh in 2023 to 160 GWh by 2030. It also estimated this could translate into electrolyte demand of over 150,000 MT by 2030 in India, and lithium electrolyte salt demand of 15,000 to 22,500 MT, based on electrolytes comprising 10 to 15 percent of lithium electrolyte salts.

Balance sheet and funding: promoter backing, higher leverage

Growth is being funded through a combination of debt and equity support. The board approved a preferential allotment of 10 lakh equity shares to a promoter group entity, aggregating to INR 161 crore, at INR 1,610 per share, around 17 percent premium to the SEBI floor price. Funds are earmarked for logistics expansion, working capital, and general corporate purposes.

Debt has risen sharply. On a consolidated basis, total debt in FY26 was INR 1,330 crore and net debt was INR 1,295 crore. On a standalone basis, total debt was INR 671 crore and net debt was INR 641 crore. The company linked the increase to targeted funding for the Dahej facility rebuild and continued capital outlay in Neogen Ionics.

The consolidated balance sheet snapshot reflected this expansion cycle. Total assets rose to INR 2,902 crore as of March 31, 2026 from INR 1,747 crore a year earlier, with non-current assets at INR 1,509 crore versus INR 747 crore. Shareholders’ funds were INR 816 crore compared with INR 789 crore, while non-current liabilities increased to INR 898 crore from INR 225 crore.

While leverage is elevated, the company disclosed liquid investments, including fixed deposits, of INR 35 crore as of March 31, 2026. Insurance receivables linked to Dahej also remain an important offset, though timing and final realization will matter.

What management is guiding to, and what to watch

Managing Director Dr. Harin Kanani framed FY26 as a year of operational resilience amid geopolitical disruption, while FY27 is positioned as a transition year with multiple commissioning milestones. He reiterated that input cost inflation remains mostly a pass-through, helping protect core profitability.

The most explicit forward marker is the standalone revenue expectation for FY27 in the range of INR 875 to 950 crore. The company also expects standalone operations to resume a normalized growth trajectory aided by the replacement plant at Dahej expected to be commissioned by June 2026.

For investors, the next year is likely to be judged on a small set of measurable outcomes.

First, Dahej commissioning and ramp-up needs to translate into stable output and better fixed-cost absorption, validating management’s expectation of a return to a normalized trajectory.

Second, Neogen Ionics needs to convert trial production and provisional approvals into repeat commercial orders. The presentation’s emphasis on audits, customer qualification, and phased ramp-up suggests management is prioritizing reliability over speed.

Third, the balance between growth investment and financial discipline will stay in focus. FY26 already showed that interest costs can quickly erode profit growth even when revenue expands at a healthy pace.

A final note is the seasonality described by the company. Neogen tends to deliver stronger financial performance in the second half of the year due to stronger demand from Europe and seasonal patterns in agrochemicals and lithium-based chemicals. That makes year-on-year comparisons by quarter more meaningful than sequential comparisons.

Neogen’s Q4 FY26 results did not resolve the trade-off between building for the next cycle and protecting near-term margins. But they showed the core business can still grow through disruption, and they outlined a funded path to scale in battery materials. FY27 will test whether commissioning at Dahej and the large Pakhajan build-out can move from project status to earnings visibility.